Skip to main content
Premium Trial:

Request an Annual Quote

William Van Nostrand, John Cassimatis, Alan Seadler, Thomas Petzinger Jr., Marc-Henri Galletti, Matthew McGinniss

Premium

William Van Nostrand and John Cassimatis were named vice presidents in the life sciences group of Long Beach, Calif.-based First Consulting Group. Van Nostrand, previously president of Dendrite’s clinical trials division in Morristown, NJ, becomes senior vice president of US sales; Cassimatis becomes VP of performance improvement.

 

Alan Seadler was named CEO of Crystalplex of Pittsburgh, effective May 1, succeeding Thomas Petzinger Jr., who will continue as chairman and CEO of LaunchCyte, which founded Crystalplex. Seadler previously was vice president of the executive corps program for the Pittsburgh Life Sciences Greenhouse. Crystalpex is preparing to commercialize labeled nanocrystal beads. Seadler holds a doctorate in biology from Case Western Reserve University.

 

Marc-Henri Galletti has joined Pequot Capital Management of New York as vice president of Pequot Ventures to focus on investments in biotechnology and medical devices. Previously, Galletti was a private equity research analyst at Amerindo Investment Advisors.

 

Matthew McGinniss has been named associate scientific director of molecular genetics for Quest Diagnostics Nichols Institute.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.